Comprehensive Mental Health Support for Women
Depression and anxiety are among the most common complications affecting women during pregnancy, postpartum recovery, fertility treatment, and menopause. These symptoms are often biologically influenced, hormonally sensitive, and under-recognized, even in well-screened patients.
At Junction Brain Health, we work alongside OB-GYN practices to provide evidence-based, specialty mental health care for women whose symptoms persist despite first-line treatment, or when medication exposure, tolerability, or response is a concern.
Our role is not to replace OB-GYN care, but to extend it by offering referral pathways that support patients while respecting the central role of women’s health providers.
Why Mental Health Is a Core Part of Women’s Health
Mood symptoms are not separate from reproductive health; they are deeply intertwined with hormonal transitions, sleep disruption, psychosocial stress, and neurobiology.
Women experience depression at nearly TWICE the rate of men, with risk increasing significantly during reproductive transitions.
Research consistently shows:
- 13-20% of women experience depression during pregnancy or within the first year postpartum
- Up to 60% of postpartum depression cases begin after delivery, often weeks or months later
- Perimenopause and menopause are associated with increased rates of new-onset depression and anxiety
- 30-40% of patients do not respond adequately to first-line antidepressants
For many women, OB-GYN visits are the only consistent medical touchpoint where mood changes are noticed, normalized, and trusted. This places OB-GYN providers in a critical position to identify symptoms, normalize experiences, and initiate referral when additional care is needed.
What OB-GYN Providers Commonly Observe (and Why It Matters)
Persistent low mood, anxiety, or emotional numbness during or after pregnancy
Sleep disruption, irritability, or withdrawal beyond expected postpartum adjustment
Depression that worsens during fertility treatment or pregnancy loss
PMDD or cyclical mood symptoms linked to hormonal changes
New or worsening depression during perimenopause or menopause
Limited response or poor tolerability with antidepressant medications
These patterns reflect brain-based mood disorders influenced by hormonal and physiologic shifts, not personal failure or lack of resilience.
Advanced Treatment Options Offered Through Junction Brain Health
TMS is an FDA-cleared, non-invasive treatment for major depressive disorder and treatment-resistant depression.
Clinical data show:
- 60–70% response rates in patients with treatment-resistant depression
- Approximately 30% achieve full remission
- No systemic medication exposure
- No sedation or cognitive impairment
- Outpatient treatment with short daily sessions
TMS uses targeted magnetic pulses to stimulate underactive areas of the brain involved in mood regulation, particularly the prefrontal cortex.
Why this matters for OB-GYNs:
Because TMS is non-systemic and drug-free, it may be an appropriate option when medication exposure, side effects, or inadequate response limit traditional approaches.
Secondary option within OB-GYN referral pathways
Spravato® is FDA-approved for adults with treatment-resistant depression and for depressive symptoms in adults with suicidal ideation.
Key clinical considerations:
- Some patients experience symptom improvement within days
- Administered in-clinic under REMS-mandated medical supervision
- Used intermittently, not as a daily medication
- Works through NMDA receptor modulation, offering a different mechanism than traditional antidepressants
Important OB-GYN context:
Spravato® is not recommended during breastfeeding per FDA labeling. For non-breastfeeding postpartum patients or those with severe, refractory depression, it may be considered through shared decision-making and coordinated care.
Consultative service for complex, hormone-sensitive cases
Medication remains an important tool, especially when used thoughtfully.
Our approach emphasizes:
- Careful review of prior medication trials and responses
- Attention to hormonal sensitivity and side-effect burden
- Evidence-based optimization strategies
- Close collaboration with OB-GYN providers
This service is designed for patients with complex presentations, not routine refills or therapy-only care.
How Junction Brain Health Supports OB-GYN Practices
A collaborative model that respects your role
We align with American College of Obstetricians and Gynecologists (ACOG) recommendations for mental health screening and referral by:
- Accepting referrals after positive depression or anxiety screens
- Providing timely psychiatric evaluation and advanced treatment options
- Maintaining clear communication with referring providers
- Supporting shared decision-making and continuity of care
Our role is to reduce the burden on OB-GYN practices while ensuring patients receive appropriate, specialty care.
What Patients Experience
Patients often arrive feeling:
- Ashamed for “not coping better”
- Concerned about medication side effects
- Emotionally disconnected from themselves or loved ones
- Unsure whether their symptoms are “normal”
Care at Junction Brain Health is:
- Compassionate and stigma-free
- Grounded in neuroscience and evidence
- Delivered by experienced clinicians and empathetic technicians
- Focused on restoring daily function, connection, and quality of life
When a Referral Makes Sense
Referral may be helpful when:
- Depression persists despite therapy or medication
- Symptoms worsen during pregnancy, postpartum, or menopause
- Side effects limit medication adherence
- Symptoms are moderate to severe on screening tools
- Additional treatment options are needed
Ready to Take the Next Step?
For OB-GYN Providers
Partner with a specialty mental health team that understands the intersection of hormones, brain health, and mood.
For Patients
If your depression feels tied to pregnancy, hormones, or life transitions, help is available.
Common Questions We Get Asked
Between 13–20% of women experience depression during pregnancy or within the first year postpartum.
Yes. Many cases emerge weeks or months postpartum, often after routine follow-up has ended.
Hormonal changes, sleep disruption, stress physiology, and neurobiology can affect response.
TMS directly stimulates brain circuits involved in mood regulation without systemic drug exposure.
TMS is non-pharmacologic and does not enter breast milk, making it a potential option when medication exposure is a concern.
Most courses last 4-6 weeks, with short outpatient sessions.
Spravato® is approved for treatment-resistant depression and depressive symptoms with suicidal ideation in adults.
In many cases, yes. Some patients experience improvement within days.
It may be considered for non-breastfeeding patients under close medical supervision.
No. It is not recommended during breastfeeding per FDA labeling.
Depression that does not adequately improve after at least two appropriate antidepressant trials.
Yes. Collaboration and communication are central to our model.
No. We complement existing care and focus specifically on mental health treatment.
Most major plans are accepted; coverage varies by treatment and location.
Patients or providers can contact Junction Brain Health to schedule an evaluation or referral discussion.
We're Here to Help
Research-Backed Insights in Women’s Mental Health
Depression During Pregnancy and Postpartum Is Common
Stat: 13–20% of women experience depression during pregnancy or within the first year postpartum.
Why this matters: Depression is among the most common pregnancy-related complications and warrants routine screening and referral.
Source: Centers for Disease Control and Prevention
https://www.cdc.gov/pcd/issues/2023/23_0107.htm
Postpartum Depression Often Begins After Delivery
Stat: More than half of postpartum depression cases begin after childbirth, often weeks or months later.
Why this matters: Symptoms may emerge after routine postpartum visits, underscoring the importance of ongoing vigilance and referral pathways.
Source: National Institutes of Health
https://pmc.ncbi.nlm.nih.gov/articles/PMC2440795/
A Subset of Women Experience Long-Term Symptoms
Stat: Approximately 2% of women with perinatal depression continue to have clinically significant symptoms 36 months postpartum.
Why this matters: Some patients require longer-term, specialized treatment beyond the immediate postpartum period.
Source: Pediatrics
https://publications.aap.org/pediatrics/article-abstract/146/5/e20200857
Many Patients Do Not Respond to First-Line Antidepressants
Stat: 30–40% of patients with major depressive disorder do not achieve adequate response to initial antidepressant therapy.
Why this matters: Referral for advanced treatment options is appropriate when first-line approaches are insufficient.
Source: American Journal of Psychiatry
TMS Is an Established Treatment for Major Depressive Disorder
Stat: TMS has demonstrated consistent response and remission rates in treatment-resistant depression across large clinical trials.
Why this matters: TMS offers a non-pharmacologic option when medication exposure or tolerability is a concern.
Source: National Institute of Mental Health
https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies